Hi, I'm
Juan Luis Onieva

Bioinformatics PhD, data scientist and immuno-oncology researcher

I integrate multi-omics data (liquid biopsy, transcriptomics, epigenetics) with machine learning to find biomarkers that predict who will respond to cancer immunotherapy.

Portrait of Juan Luis Onieva
Who I am

About me

I hold a PhD in Biomedicine, Translational Research and New Health Technologies from the University of Málaga (Faculty of Medicine), awarded Sobresaliente Cum Laude with International Mention. My thesis, presented as a compendium of publications, focused on developing and applying bioinformatics and artificial intelligence methods to integrate multi-omic data and identify predictive biomarkers of response to cancer immunotherapy.

My work spans from early discovery (Int J Mol Sci, 2022; Cancers, 2023) to validation in high-impact journals (J Immunother Cancer, 2026; OncoImmunology, 2026). During my doctorate I carried out research stays at the Karolinska Institutet and the German Cancer Research Center (DKFZ), and I complement research with knowledge transfer: patents, the IMFAHE Shark Tank and Tesis Talk UMA.

I love solving problems, discovering new tools in data science, and above all, sharing knowledge.

Multi-omics integrationMachine learningLiquid biopsycfDNA methylationRNA-seq / scRNA-seqFlow cytometryImmunotherapy biomarkers
Based in
Málaga, Spain
Current role
Area Coordinator & Bioinformatician
Affiliation
IBIMA Plataforma BIONAND
Teaching
Associate Professor, UC3M

Multi-omics biomarkers

Integrating cfDNA methylation, extracellular-vesicle miRNAs, transcriptomics and germline variation to stratify patients treated with immune checkpoint inhibitors.

AI for precision oncology

Machine-learning risk scores and predictive signatures for lung cancer, melanoma and breast cancer, built to be validated across cohorts.

Liquid biopsy

Minimally invasive monitoring of response and resistance to immunotherapy and radiotherapy (SABR) from blood samples.

Tumour & immune cells

Single-cell and bulk transcriptomics plus flow cytometry to understand primary resistance to checkpoint blockade.

Career

Experience

  1. 2026 – present

    Area Coordinator & Bioinformatician

    Centro de Investigación y Terapias Avanzadas del Cáncer

  2. 2026 – present

    Associate Professor

    Universidad Carlos III de Madrid

  3. 2019 – 2026

    Predoctoral Researcher & Bioinformatician

    IBIMA Plataforma BIONAND · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

  4. 2020 – 2021

    Bioinformatician

    Biomage Ltd.

  5. Jul – Sep 2018

    CICERONE Bioinformatician

    CNIC — Centro Nacional de Investigaciones Cardiovasculares Carlos III

Research stays

DKFZ — German Cancer Research CenterGermany · Aug – Nov 2024
Karolinska InstitutetSweden · Sep – Dec 2023
Training

Education

  1. 2021 – 2026

    PhD in Biomedicine, Translational Research and New Health Technologies

    University of Málaga

    ★ Sobresaliente Cum Laude · International Mention

  2. 2019 – 2020

    Master in Statistics for Data Science

    Universidad Carlos III de Madrid

  3. 2017 – 2018

    Bachelor in Health Engineering (Erasmus)

    Charles University, Prague

  4. 2015 – 2019

    Bachelor in Health Engineering

    University of Málaga

    ★ Premio Nacional Fin de Carrera en Ingeniería de la Salud

Scientific output

Publications

Selected from my CVN. Full record on ORCID. ORCID →

  1. 2026
  2. 2026

    Molecular and clinical predictors of NAC response and relapse in HR+/HER2− early breast cancer

    Chica-Parrado MR, Onieva JL, et al.

    Breast Cancer Research

    Author 2/12 JCR 6.2
  3. 2026
  4. 2026
  5. 2026

    Integrating Tumor and Immune Cell Transcriptomics to Predict Immune Checkpoint Inhibitor Primary Resistance in Metastatic Melanoma

    Onieva JL, Pérez-Ruiz E, Vilkki V, et al.

    OncoImmunology · 15(1)

    First author Author 1/9 JCR 6.2
  6. 2026

    Integrative Multi-Omic Profiling of cfDNA Methylation and EV-miRNAs Identifies Immunotherapy-Outcome Molecular Subtypes in NSCLC

    Onieva JL, Pérez-Ruiz E, Figueroa-Órtiz L, et al.

    Journal for ImmunoTherapy of Cancer

    First author Author 1/8 JCR 11.7
  7. 2025

    Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma

    Guardamagna M, Berciano-Guerrero MA, Lavado-Valenzuela R, et al.

    Scientific Reports · 15:25430

    Author 4/19 JCR 4.9
  8. 2024

    Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer

    Zafra J, Onieva JL, Oliver J, et al.

    International Journal of Molecular Sciences · 25(8):4533

    First author · Shared first authorship Author 2/15 JCR 4.9
  9. 2023

    Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade

    Oliver J, Onieva JL, Garrido-Barros M, et al.

    Cancers · 15:3357

    First author · Shared first authorship Author 2/13 JCR 4.5
  10. 2022

    Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma

    Oliver J, Onieva JL, Garrido-Barros M, et al.

    Biomedicines · 10(10):2419

    First author · Shared first authorship Author 2/14 JCR 4.7
  11. 2022

    High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade

    Onieva JL, Xiao Q, Berciano-Guerrero MA, et al.

    International Journal of Molecular Sciences · 23(16):9124

    First author Author 1/23 JCR 5.6
  12. 2022

    Combination of SABR with anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma: results of a prospective multicenter observational study

    Chicas-Sett R, Zafra J, Rodriguez-Abreu D, et al.

    Int. J. Radiation Oncology Biol. Phys. · 114(4):655–665

    Author 9/10 JCR 7.0
  13. 2022

    Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy

    Berciano-Guerrero MA, Lavado-Valenzuela R, Moya A, et al.

    Biomedicines · 10(2):284

    Author 10/14 JCR 4.7
  14. 2021

    Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction

    Oliver J, García-Aranda M, Chaves P, Alba E, Cobo-Dols M, Onieva JL, Barragán I

    Seminars in Cancer Biology · 83:584–595

    Author 6/7 JCR 17.0
  15. 2021

    Epigenetic biomarkers of disease

    Chavez P, Onieva JL, Barragán I

    Medical Epigenetics (book chapter)

    Author 2/3Book chapter
  16. 2025
  17. 2024
  18. 2023
  19. 2023

    Genetic Susceptibility to Immune Checkpoints Blockade Resistance

    Journal of Thoracic Oncology 18(11):S234

    Meeting abstract
  20. 2023
  21. 2023
  22. 2022
  23. 2022
  24. 2021
  25. 2020
  26. 2020
  27. 2020
Grants

Funded research projects

I have taken part in 14 competitive projects at IBIMA Plataforma BIONAND, funded by national and regional agencies and scientific societies.

2026–2030PI26/01945

Multi-omic panels and multidimensional integration to predict clinical benefit of SBRT in tumours refractory to immunotherapy

Instituto de Salud Carlos III

2025–2027CI25-20197

EPIPREDICT: epigenetic decoding of blood DNA to predict clinical benefit of immunotherapy

Fundación “la Caixa”

2024–2027PRYES247250BARR

EPI-SABR: deciphering the epigenetic signatures of the abscopal response towards precision immunotherapy

Fundación Científica AECC

2024–2026DTS23/00114

EPIPREDICT: epigenetic markers in liquid biopsy to predict response and prognosis with novel IO approaches

Instituto de Salud Carlos III

2024–2025CNS2023-145629

MAPS-LUNG: multimodal, multiscale AI and transcriptomics system to predict distant relapse in lung cancer

Agencia Estatal de Investigación

2023–2025ProyExcel_01002

Precision pharmacogenomics applied to immunotherapy in lung and head & neck cancer

Junta de Andalucía

2022–2025PI22/01816

Immunotherapy resistance biomarkers: integrating abscopal effect and epigenetics for non-invasive precision medicine

Instituto de Salud Carlos III

2020–2023PI-0121-2020

Longitudinal study of genetic and epigenetic variants and cell populations as markers of response to checkpoint inhibitors in melanoma

Junta de Andalucía

2021–2023CPC21201_SEOM

Early detection of hepatic metastasis in breast cancer using cfDNA methylation and hydroxymethylation

Sociedad Española de Oncología Médica

2021–2022P20-01326

ORIGEN: early detection of hepatic metastasis in breast cancer from circulating cfDNA

Junta de Andalucía

2020–2022COV20-62050

Susceptibility factors for SARS-CoV-2 infection and severity in cancer patients on checkpoint inhibitors

Instituto de Salud Carlos III

2020–2022GEM20_001

Genetic and epigenetic variants associated with response to checkpoint inhibitors in cancer

Grupo Español de Melanoma

2021–2022SEOM20_001_TAKEDA

Exosomal circular RNAs as response biomarkers to immunotherapy in non-small cell lung cancer

Sociedad Española de Oncología Médica

2019–2020PI18-01592

Omics integration for targeted immunotherapy: towards liquid biopsy

Instituto de Salud Carlos III

Patents & transfer

Method to predict response and prognosis to immunotherapy treatment in cancer

Registered 11/08/2025

circRNA profile for predicting immunotherapy response in cancer patients

Registered 26/05/2023

ceRNA profile to predict response to immunotherapy in cancer patients

Registered 26/05/2022

Talks

Conferences & distinctions

ISMB/ECCB 2023 — Best Poster Award at TransMed

Machine learning on flow cytometry data to predict checkpoint blockade response

EACR Travel Grant

European Association for Cancer Research, Italy 2024

Premio Nacional Fin de Carrera

Ingeniería de la Salud

  • 2026
    Patología Digital y Deep Learning: del píxel al fenotipoXXXIII Congreso SEHIT, Spain · Oral communication
  • 2024
    Multi-Omics Profiling in Immune Checkpoint Inhibition Response: Revealing Longitudinal Regulatory Biomarkers via Liquid Biopsy AnalysisEACR Cancer Genomics, Multiomics & Computational Biology, Italy · Congress
  • 2024
    Multi-omics Integration for Biomarker Discovery in Cancer ImmunotherapyIV Concurso Thesis Talk — Escuela de Doctorado, Universidad de Málaga · Talk
  • 2023
    Machine Learning on flow cytometry data to develop a predictive signature for ICB in melanoma and NSCLCISMB/ECCB 2023, France · Poster · Best Poster
  • 2022
    Early cfDNA quantification as response and survival marker in immunotherapy-treated patientsCongreso SEOM 2022, Spain · Congress
Contact

Let's collaborate

Interested in multi-omics, immunotherapy biomarkers or data science in oncology? I'm happy to talk about collaborations, projects or supervision.

Send me an email

juanluonieva@gmail.com